Preoperative paraspinous muscle sarcopenia and physical performance as prognostic indicators in non-small-cell lung cancer.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
06 2021
Historique:
revised: 12 01 2021
received: 23 09 2020
accepted: 01 02 2021
pubmed: 6 3 2021
medline: 26 11 2021
entrez: 5 3 2021
Statut: ppublish

Résumé

Despite the associations of both preoperative sarcopenia and physical performance with post-operative mortality in non-small-cell lung cancer (NSCLC), there have been no comprehensive studies of the impact of physical status on prognosis. This study was performed to investigate the prognostic significance of preoperative sarcopenia and physical performance in NSCLC. This retrospective cohort study was performed in NSCLS patients undergoing curative lung resection at a university hospital between January 2014 and December 2017. The patients were divided into four groups according to the skeletal muscle index [sarcopenia (lowest sex-specific tertile) and non-sarcopenia] and 6 min walking distance (6MWD) [short distance (<400 m) and long distance (≥400 m)]. Sarcopenia was assessed by preoperative cross-sectional areas of right and left paraspinous muscles at the level of the 12th thoracic vertebra from computed tomography images, and physical performance was determined by preoperative 6MWD. The primary and secondary endpoints were post-operative overall survival (OS) and disease-free survival (DFS). The 587 patients [mean age: 68.5 ± 8.8 years, 399 men (68%)] included in the study were divided into the non-sarcopenia/long-distance group (58%), sarcopenia/long-distance group (26%), non-sarcopenia/short-distance group (9%), and sarcopenia/short-distance group (7%). A total of 109 (18.6%) deaths and 209 (35.6%) combined endpoints were observed over a mean follow-up of 3.1 ± 1.3 years. After adjusting for other covariates, the sarcopenia/short-distance group showed significant associations with shorter OS (hazard ratio, 3.38; 95% confidence interval, 1.79-6.37; P < 0.001) and DFS (hazard ratio, 2.11; 95% confidence, 1.27-3.51; P = 0.004) compared with the non-sarcopenia/long-distance group on multivariate analyses. Although not significant, adding skeletal muscle index and 6MWD to the pre-existing risk model increased the area under the curve on time-dependent receiver operating characteristic curve analysis for OS and DFS, except within 2 years of surgery. The presence of both preoperative paraspinous muscle sarcopenia and short distance in 6MWD had an adverse effect on post-operative prognosis in patients with NSCLC, suggesting that preoperative assessment of thoracic sarcopenia and physical performance may be useful for risk stratification of surgical candidates with potential for targeted interventions.

Sections du résumé

BACKGROUND
Despite the associations of both preoperative sarcopenia and physical performance with post-operative mortality in non-small-cell lung cancer (NSCLC), there have been no comprehensive studies of the impact of physical status on prognosis. This study was performed to investigate the prognostic significance of preoperative sarcopenia and physical performance in NSCLC.
METHODS
This retrospective cohort study was performed in NSCLS patients undergoing curative lung resection at a university hospital between January 2014 and December 2017. The patients were divided into four groups according to the skeletal muscle index [sarcopenia (lowest sex-specific tertile) and non-sarcopenia] and 6 min walking distance (6MWD) [short distance (<400 m) and long distance (≥400 m)]. Sarcopenia was assessed by preoperative cross-sectional areas of right and left paraspinous muscles at the level of the 12th thoracic vertebra from computed tomography images, and physical performance was determined by preoperative 6MWD. The primary and secondary endpoints were post-operative overall survival (OS) and disease-free survival (DFS).
RESULTS
The 587 patients [mean age: 68.5 ± 8.8 years, 399 men (68%)] included in the study were divided into the non-sarcopenia/long-distance group (58%), sarcopenia/long-distance group (26%), non-sarcopenia/short-distance group (9%), and sarcopenia/short-distance group (7%). A total of 109 (18.6%) deaths and 209 (35.6%) combined endpoints were observed over a mean follow-up of 3.1 ± 1.3 years. After adjusting for other covariates, the sarcopenia/short-distance group showed significant associations with shorter OS (hazard ratio, 3.38; 95% confidence interval, 1.79-6.37; P < 0.001) and DFS (hazard ratio, 2.11; 95% confidence, 1.27-3.51; P = 0.004) compared with the non-sarcopenia/long-distance group on multivariate analyses. Although not significant, adding skeletal muscle index and 6MWD to the pre-existing risk model increased the area under the curve on time-dependent receiver operating characteristic curve analysis for OS and DFS, except within 2 years of surgery.
CONCLUSIONS
The presence of both preoperative paraspinous muscle sarcopenia and short distance in 6MWD had an adverse effect on post-operative prognosis in patients with NSCLC, suggesting that preoperative assessment of thoracic sarcopenia and physical performance may be useful for risk stratification of surgical candidates with potential for targeted interventions.

Identifiants

pubmed: 33665984
doi: 10.1002/jcsm.12691
pmc: PMC8200441
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

646-656

Informations de copyright

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Integr Cancer Ther. 2017 Mar;16(1):63-73
pubmed: 27151583
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
Oncologist. 2020 Mar;25(3):e555-e569
pubmed: 32162811
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
J Am Med Dir Assoc. 2011 Jul;12(6):403-9
pubmed: 21640657
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):424-431
pubmed: 32045108
Lung Cancer. 2019 Feb;128:47-52
pubmed: 30642452
Nat Rev Cancer. 2014 Nov;14(11):754-62
pubmed: 25291291
Lancet. 2019 Oct 12;394(10206):1365-1375
pubmed: 31609228
Chest. 2013 May;143(5 Suppl):e166S-e190S
pubmed: 23649437
Clin Nutr. 2016 Aug;35(4):924-7
pubmed: 26205321
J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):646-656
pubmed: 33665984
Int J Clin Oncol. 2020 May;25(5):876-884
pubmed: 31955305
Gen Thorac Cardiovasc Surg. 2016 Oct;64(10):569-76
pubmed: 27501695
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):507-509
pubmed: 27891294
J Thorac Dis. 2018 Jan;10(1):432-440
pubmed: 29600075
Ann Thorac Surg. 2019 Nov;108(5):1555-1564
pubmed: 31228408
Chest. 2019 Jul;156(1):101-111
pubmed: 31128115
Sci Rep. 2020 Feb 11;10(1):2312
pubmed: 32047177
Cancers (Basel). 2019 Jul 05;11(7):
pubmed: 31284372
Lung Cancer. 2018 May;119:91-98
pubmed: 29656759
JAMA Surg. 2020 Jul 1;155(7):662-664
pubmed: 32347915
Lung Cancer. 2014 Feb;83(2):292-9
pubmed: 24360323
Stat Med. 2013 Dec 30;32(30):5381-97
pubmed: 24027076
Chest. 2020 Jun;157(6):1665-1673
pubmed: 31987880
J Thorac Oncol. 2016 Sep;11(9):1397-410
pubmed: 27156441
Stat Med. 1999 Mar 30;18(6):681-94
pubmed: 10204197
Respirology. 2020 Nov;25 Suppl 2:80-87
pubmed: 32567236
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):956-961
pubmed: 31523937
Am J Med. 2006 Jun;119(6):526.e9-17
pubmed: 16750969
Eur J Cardiothorac Surg. 2017 Nov 1;52(5):969-974
pubmed: 28520857
Maturitas. 2020 Aug;138:69-75
pubmed: 32471663
Ann Am Thorac Soc. 2016 Mar;13(3):334-41
pubmed: 26700501
J Am Med Dir Assoc. 2021 Apr;22(4):846-852
pubmed: 33232685
Gen Thorac Cardiovasc Surg. 2021 Feb;69(2):282-289
pubmed: 32761511
Interact Cardiovasc Thorac Surg. 2018 Feb 1;26(2):277-283
pubmed: 29049742
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
BMC Cancer. 2013 Mar 20;13:135
pubmed: 23514337
Chest. 2013 May;143(5 Suppl):e142S-e165S
pubmed: 23649436
J Gerontol A Biol Sci Med Sci. 2002 May;57(5):M326-32
pubmed: 11983728
Chest. 2020 Mar;157(3):603-611
pubmed: 31689414
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S454-S459
pubmed: 32038937
J Thorac Oncol. 2015 Jul;10(7):990-1003
pubmed: 26134221

Auteurs

Shinya Tanaka (S)

Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.

Naoki Ozeki (N)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yota Mizuno (Y)

Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.

Hiroki Nakajima (H)

Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.

Keiko Hattori (K)

Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.

Takayuki Inoue (T)

Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.

Motoki Nagaya (M)

Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.

Takayuki Fukui (T)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Shota Nakamura (S)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Masaki Goto (M)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Tomoshi Sugiyama (T)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yoshihiro Nishida (Y)

Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.
Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.

Toyofumi Fengshi Chen-Yoshikawa (TF)

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH